Related Experiment Video
Updated: Jul 18, 2026
08:53
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Brand versus generic alendronate: gastrointestinal effects measured by resource utilization
Hillel Halkin1, Marina Dushenat, Barbara Silverman
1Chairman, Formulary Committee, Maccabi Healthcare Services, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University.
The Annals of Pharmacotherapy
|December 28, 2006
Summary
Generic alendronate formulations showed higher discontinuation rates and lower adherence compared to the brand drug. However, insufficient evidence suggests no major differences in upper gastrointestinal adverse effects.
Area of Science:
- Pharmacology
- Gastroenterology
- Drug Safety
Background:
- Upper gastrointestinal tract (UGIT) adverse reactions may vary between generic and brand alendronate formulations.
- Understanding these differences is crucial for patient safety and treatment efficacy.
Purpose of the Study:
- To investigate whether adverse upper gastrointestinal (UGIT) effects differ between generic and brand alendronate formulations.
- To compare treatment discontinuation, adherence, and UGIT-related outcomes.
Main Methods:
- A retrospective database analysis of 6962 patients using alendronate formulations (brand and generic) from 2001-2005.
- Compared incidence rates of new gastric medication use, gastroenterology visits, endoscopies, and hospital admissions.
- Adjusted for concurrent use of corticosteroids, NSAIDs, and potassium supplements.
Main Results:
- Daily generic alendronate showed higher treatment discontinuation rates (IRR 1.3) and lower adherence.
- Brand alendronate (10 mg/day) demonstrated lower new use of gastric medications (IRR 0.71).
- Hospitalization rates were similar across all groups; endoscopic findings showed no significant formulation differences.
Conclusions:
- Insufficient evidence indicates major differences in UGIT adverse effects between daily generic and brand alendronate.
- While adherence and discontinuation varied, significant UGIT safety concerns did not emerge.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:21Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...